Information
Piroxicam Piroxicam (CP 16171) is a non-selective COX inhibitor, used in the treatment of rheumatoid and osteoarthritis.
In vitro
Piroxicam induces activation of extracellular signal-regulated kinase (ERK) in neurones and phosphorylation of heavy molecular weight neurofilaments, cytoskeletal substrates of ERK in rat spinal cord cultures. Piroxicam and NS-398 protect neurones against hypoxia/reperfusion in rat spinal cord cultures.
In vivo
Piroxicam at doses higher than 0.04%, strongly inhibits the development of GST-P-positive and neoplastic nodules as well as fibrosis, cirrhosis and formation of 8-hydroxydeoxyguanosine (8-OHdG) adducts in rats. Piroxicam increases the expression of all three MHC antigens compared to either control or azoxymethane (AOM)-treated rats. Piroxicam up-regulates colonic MHC antigen expression in the AOM model of colonic carcinogenesis. Piroxicam combined with Cisplatin has antitumor activity against oral malignant melanoma (OMM) and oral squamous cell carcinoma (SCC) in rats. Piroxicam inhibits prostaglandin synthesis through cyclooxygenase blockade in dog, and Piroxicam does not have any direct cytotoxic effects in vitro. Piroxicam also binds strongly to plasma proteins and Piroxicam could stop Ochratoxin A (OTA) -binding and transport into target organs, thereby preventing its nephrotoxicity in rats. Piroxicam prevents the enzymuria induced by OTA and increases renal elimination of OTA in rats.
Cell Data
cell lines：S114, GTL-16, NCI-H441, and BxPC-3
Concentrations：
Incubation Time：
Powder Purity:≥100%
